{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T21:38:06Z","timestamp":1649108286130},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T00:00:00Z","timestamp":1437955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T00:00:00Z","timestamp":1437955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/bmt.2015.169","type":"journal-article","created":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T13:41:23Z","timestamp":1438004483000},"page":"1480-1482","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis"],"prefix":"10.1038","volume":"50","author":[{"given":"P","family":"Torka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Paplham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,27]]},"reference":[{"key":"BFbmt2015169_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","volume":"2011","author":"F Cervantes","year":"2011","unstructured":"Cervantes F . Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 215\u2013221.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2015169_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/bmt.2013.167","volume":"49","author":"GL Chen","year":"2014","unstructured":"Chen GL, Zhang Y, Hahn T, Abrams S, Ross M, Liu H et al. Acute GvHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine\/melphalan conditioning. Bone Marrow Transplant 2014; 49: 248\u2013253.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR3","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264\u20135270.","journal-title":"Blood"},{"key":"BFbmt2015169_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","volume":"124","author":"D Rondelli","year":"2014","unstructured":"Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 2014; 124: 1183\u20131191.","journal-title":"Blood"},{"key":"BFbmt2015169_CR5","first-page":"801","volume":"18","author":"M Wakui","year":"1996","unstructured":"Wakui M, Okamoto S, Ishida A, Tanosaki R, Mori T, Kawai Y et al. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 801\u2013804.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.bmt.1701379","volume":"22","author":"J Serrano","year":"1998","unstructured":"Serrano J, Roman J, Castillejo JA, Sanchez J, Navarro JA, Martin C et al. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML. Bone Marrow Transplant 1998; 22: 599\u2013601.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/sj.bmt.1702696","volume":"26","author":"CG Brunstein","year":"2000","unstructured":"Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB et al. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplant 2000; 26: 1173\u20131177.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.bmt.1703218","volume":"28","author":"S Maury","year":"2001","unstructured":"Maury S, Belhadj K, Chami I, Kuentz M, Cordonnier C, Bories D . Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population. Bone Marrow Transplant 2001; 28: 717\u2013720.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bmt.2009.96","volume":"45","author":"E Daguindau","year":"2010","unstructured":"Daguindau E, Lioure B, Buzyn A, Robin M, Faucher C, Kuentz M et al. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. Bone Marrow Transplant 2010; 45: 177\u2013180.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/sj.bmt.1704617","volume":"34","author":"OF Ballester","year":"2004","unstructured":"Ballester OF, Fang T, Raptis A, Ballester G, Wilcox P, Hiemenz J et al. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Bone Marrow Transplant 2004; 34: 419\u2013423.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015169_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2141.2004.05328.x","volume":"128","author":"BR Dey","year":"2005","unstructured":"Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351\u2013359.","journal-title":"Br J Haematol"},{"key":"BFbmt2015169_CR12","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/blood-2002-12-3949","volume":"102","author":"MT Rubio","year":"2003","unstructured":"Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M . Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 2003; 102: 2300\u20132307.","journal-title":"Blood"},{"key":"BFbmt2015169_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377\u20131380.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015169","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:18:45Z","timestamp":1648059525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,27]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFbmt2015169"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.169","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,27]]},"assertion":[{"value":"27 July 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}